Gamunex-C FDA Approval History
FDA Approved: Yes (First approved October 13, 2010)
Brand name: Gamunex-C
Generic name: immune globulin intravenous and subcutaneous
Dosage form: Injection
Company: Talecris Biotherapeutics, Inc.
Treatment for: Primary Immunodeficiency Syndrome
Gamunex-C (immune globulin intravenous and subcutaneous) is indicated for the treatment of primary immunodeficiency (PI).
Development timeline for Gamunex-C
|Oct 14, 2010||Approval Talecris Biotherapeutics Receives FDA Approval for Gamunex-C|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.